Egypt Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Egyptian Diabetes Drugs Market Report is Segmented Into Drugs (Insulin Drugs (Basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, and Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, and Meglitinides), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists and Amylin Analogue), and Combination Drugs (Insulin Combinations and Oral Combinations)). The Market Provides the Value (USD) for the Above-Mentioned Segments.

Egypt Diabetes Drugs Market Size

Egypt Diabetes Drugs Market Summary
View Global Report

Egypt Diabetes Drugs Market Analysis

The Egypt Diabetes Drugs Market size is estimated at USD 427.14 million in 2025, and is expected to reach USD 495.41 million by 2030, at a CAGR of 3.01% during the forecast period (2025-2030).

The Egyptian diabetes drug market is driven by factors such as the rising prevalence of diabetes in Egypt and advancement in treatment options and government initiatives.

The increasing burden of diabetes in Egypt is significantly boosting the market for diabetes drugs. The prevalence of diabetes in Egypt has risen sharply due to factors such as urbanization, dietary changes, and sedentary lifestyles, which have created a substantial demand for effective diabetes management solutions. This rising incidence drives the need for a variety of diabetes medications, including oral hypoglycemics and insulin therapies, to manage and control blood sugar levels. For instance, according to the International Diabetes Federation (IDF) data published in 2022, the number of adults with diabetes in Egypt is projected to rise to 9.5 million by 2030 and 11.8 million by 2045.

In addition, as per a study article published in BMC Public Health in May 2023, Egypt has the 9th highest prevalence of diabetes worldwide, with around 18.4% of adults affected. This equates to over 11 million people with diagnosed type 2 diabetes. Diabetes is a major cause of premature mortality, morbidity, and loss of economic growth in Egypt. Sedentary lifestyles and unhealthy dietary habits, including increased consumption of processed foods, sugary drinks, and red meat, are contributing to the rise in diabetes prevalence in Egypt. Thus, the high burden of diabetes in Egypt is expected to increase demand for effective management, thereby contributing to market growth during the forecast period.

Further, government initiatives in Egypt are crucial in boosting the market for diabetes drugs. The Egyptian government has implemented various health policies and programs to tackle the rising prevalence of diabetes, including subsidized healthcare services, public awareness campaigns, and screening programs. These initiatives enhance early diagnosis and treatment, leading to increased demand for diabetes medications.

For instance, in March 2024, under the leadership of Dr. Ahmed El-Sobky, the Chairman of the Board and Supervisor General of the Universal Health Insurance and Haya Kareema projects at the Ministry of Health and Population, the Egypt Healthcare Authority unveiled the "Ramadan Health for the Whole Family" initiative. This initiative will be rolled out across provinces implementing the universal health insurance system. Dr. El-Sobky further elaborated that the initiative focuses on medical monitoring for three patient categories: individuals with diabetes, those with hypertension, and patients presenting both conditions. Thus, the government’s efforts to prioritize diabetes management in public health strategies and support the availability of innovative therapies, these initiatives are driving both demand and investment in the diabetes drug market.

Further, strategic activities by industry players in the country are expected to increase access to diabetes drugs, contributing to the market expansion during the forecast period. For instance, in December 2022, Egypt's Medical Union Pharmaceutical Company (MUP) unveiled a new high-capacity insulin production line, as announced by Khaled Abdel-Ghaffar, the Minister of Health and Population.

The high burden of diabetes, increasing government initiatives, and key strategic activities by market players in the country are all important factors. However, the high cost of treatment and limited infrastructure in the country are expected to restrain the market during the projected period.

Egypt Diabetes Drugs Industry Overview

The Egyptian diabetes drugs market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players in the region. A large portion of the market is dominated by manufacturers consistently entering the market to create new revenue streams and enhance existing ones through strategy-based mergers and acquisitions.

Egypt Diabetes Drugs Market Leaders

  1. AstraZeneca

  2. Boehringer Ingelheim

  3. Novo Nordisk A/S

  4. Sanofi Aventis

  5. Eli Lilly and Company

  6. *Disclaimer: Major Players sorted in no particular order
Egypt Diabetes Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Egypt Diabetes Drugs Market News

  • March 2024: Egypt announced the export of lifesaving insulin injections to Cuba. The Insulinagypt injections, manufactured in Egypt for diabetes treatment, would be shipped via the United Company for Pharmaceuticals, a subsidiary of the ACDIMA Group.
  • May 2023: Eli Lilly partnered with Egypt to manufacture insulin for Africa. Eli Lilly supplies EVA Pharma in Egypt with active pharmaceutical ingredients (API) for insulin at a notably discounted rate. This initiative aims to accelerate and reduce the cost of producing this essential medication, which is crucial for treating diabetes, a rapidly escalating health concern across the continent. Also, Eli Lilly is offering a pro-bono technology transfer, empowering EVA Pharma to formulate, fill, and finalize insulin vials and cartridges. This effort aligns with Eli Lilly's global commitment to facilitate 30 million insulin doses by 2030.

Egypt Diabetes Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Diabetes
    • 4.2.2 Advancements in Treatment Options and Active Government Initiatives
  • 4.3 Market Restraints
    • 4.3.1 High Treatment Costs and Limited Healthcare Infrastructure
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Insulins
    • 5.1.1 Basal or Long-acting Insulins
    • 5.1.2 Bolus or Fast-acting Insulins
    • 5.1.3 Traditional Human Insulins
    • 5.1.4 Biosimilar Insulins
  • 5.2 Oral Anti-diabetic drugs
    • 5.2.1 Biguanides
    • 5.2.2 Alpha-glucosidase Inhibitors
    • 5.2.3 Dopamine D2 Receptor Agonist
    • 5.2.4 SGLT-2 Inhibitors
    • 5.2.5 DPP-4 Inhibitors
    • 5.2.6 Sulfonylureas
    • 5.2.7 Meglitinides
  • 5.3 Non-insulin Injectable drugs
    • 5.3.1 GLP-1 Receptor Agonists
    • 5.3.2 Amylin Analogue
  • 5.4 Combination Drugs
    • 5.4.1 Insulin Combinations
    • 5.4.2 Oral Combinations

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk A/S
    • 7.1.2 Takeda
    • 7.1.3 Pfizer
    • 7.1.4 Eli Lilly
    • 7.1.5 Janssen Pharmaceuticals
    • 7.1.6 Astellas
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Merck and Co.
    • 7.1.9 AstraZeneca
    • 7.1.10 Bristol Myers Squibb
    • 7.1.11 Julphar
    • 7.1.12 Novartis
    • 7.1.13 Sanofi Aventis
  • *List Not Exhaustive

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Egypt Diabetes Drugs Industry Segmentation

Diabetes drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Egyptian diabetes drugs market is segmented into drugs.

The Egyptian diabetes drugs market is segmented into insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. By insulin, the market is segmented as basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, and biosimilar insulins. By oral anti-diabetic drugs, the market is segmented as biguanides, alpha-glucosidase inhibitors, dopamine D2 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and meglitinides. By non-insulin injectable drugs, the market is segmented as GLP-1 receptor agonists amylin analog. The market is segmented by combination drugs into insulin and oral combinations.

The report offers the value (USD) for the above segments.

Insulins Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Oral Anti-diabetic drugs Biguanides
Alpha-glucosidase Inhibitors
Dopamine D2 Receptor Agonist
SGLT-2 Inhibitors
DPP-4 Inhibitors
Sulfonylureas
Meglitinides
Non-insulin Injectable drugs GLP-1 Receptor Agonists
Amylin Analogue
Combination Drugs Insulin Combinations
Oral Combinations
Need A Different Region or Segment?
Customize Now

Egypt Diabetes Drugs Market Research FAQs

How big is the Egypt Diabetes Drugs Market?

The Egypt Diabetes Drugs Market size is expected to reach USD 427.14 million in 2025 and grow at a CAGR of 3.01% to reach USD 495.41 million by 2030.

What is the current Egypt Diabetes Drugs Market size?

In 2025, the Egypt Diabetes Drugs Market size is expected to reach USD 427.14 million.

Who are the key players in Egypt Diabetes Drugs Market?

AstraZeneca, Boehringer Ingelheim, Novo Nordisk A/S, Sanofi Aventis and Eli Lilly and Company are the major companies operating in the Egypt Diabetes Drugs Market.

What years does this Egypt Diabetes Drugs Market cover, and what was the market size in 2024?

In 2024, the Egypt Diabetes Drugs Market size was estimated at USD 414.28 million. The report covers the Egypt Diabetes Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Egypt Diabetes Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Egypt Diabetes Drugs Industry Report

Statistics for the 2025 Egypt Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Egypt Diabetes Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Egypt Diabetes Drugs Market Report Snapshots

Compare market size and growth of Egypt Diabetes Drugs Market with other markets in Healthcare Industry

Egypt Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)